1 |
Zhu FS, Chen XM, Wang YJ, et al (2007). Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro. Chinese Journal of Oncology, 29, 186-8.
|
2 |
Klepin HD, Balducci L (2009). Acute myelogenous leukemia in older adults. Oncologist, 14, 222-32.
DOI
|
3 |
Shi H, Lu D, Shu Y, et al (2008). Expression of multidrugresistance-related proteins P-glycoprotein, glutathione-Stransferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest, 26, 344-51.
DOI
|
4 |
Zhang Y, Qu X, Hu X, et al (2009). Reversal of P-glycoproteinmediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastricadenocarcinoma cells. J Pathol, 218, 248-55.
DOI
|
5 |
Basaran H, Koca T, Cerkesli AK, et al (2015). Treatment outcomes and survival study of gastric cancer patients: a retrospective analysis in an endemic region. Asian Pac J Cancer Prev, 16, 2055-60.
DOI
|
6 |
Fagoonee S, Li H, Zhang H, et al (2014). Gastric cancer as a stem-cell disease: data and hypotheses. Panminerva Med, 56, 289-300.
|
7 |
Hua HK, Jin C, Yang LJ, et al (2015). Expression of cyclooxygenase-2 in squamous cell carcinoma and keratoacanthoma and its clinical significance. Cell Biochem Biophys, Epub ahead of print.
|
8 |
Liu H, Huang P, Xu X, et al (2009). Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells. Dig Dis Sci, 54, 1418-24.
DOI
|
9 |
He CZ, Zhang KH (2013). Serum protein and genetic tumor markers of gastric carcinoma. Asian Pac J Cancer Prev, 14, 3437-42.
DOI
ScienceOn
|
10 |
Li XF, Liu AY, Li J, et al (2015). Expression of MGMT, hMLH1 and XRCC1 in gastric cancer tissue and their clinical significance. J Int Transl Med, 3, 535-40.
|
11 |
Lu JW, Gao CM, Wu JZ, et al (2013). Polymorphism in the methylenetetrahydrofolate reductase and thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced gastric cancer patients. J Int Transl Med, 1, 4-12.
|
12 |
Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of Yadanzi(R) (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12.
DOI
ScienceOn
|
13 |
Misron NA, Looi LM, Nik Mustapha NR (2015). Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression. Asian Pac J Cancer Prev, 16, 1553-8.
DOI
|
14 |
Segawa E, Sakurai K, Kishimoto H, et al (2008). Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa. Oral Oncol, 44, 664-71.
DOI
|
15 |
Shao Y, Sun K, Xu W, et al (2014). Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis. World J Gastroenterol, 20, 12860-73.
DOI
|
16 |
Tsuruo T, Naito M, Tomida A, et al (2003). Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci, 94, 15-21.
DOI
|
17 |
Sierra JC, Hobbs S, Chaturvedi R, et al (2013). Induction of COX-2 expression by Helicobacter pylori is mediated by activation of epidermal growth factor receptor in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol, 305, G196-203.
DOI
|
18 |
Sui H, Zhou S, Wang Y, et al (2011). COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis, 32, 667-75.
DOI
|
19 |
Tan BB, Li Y, Han J, et al (2010). Relationship of cyclooxygenase-2 and multidrug resistance associated factors to chemosensitivities ingastrointestinal carcinomas. J Sichuan University (Medical Edition), 41, 128-31.
|
20 |
Wang Z, Chen JQ, Liu JL (2014). COX-2 inhibitors and gastric cancer. Gastroenterol Res Pract, Epub ahead of print.
|
21 |
Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6.
DOI
ScienceOn
|
22 |
Xu L, Stevens J, Hilton MB, et al (2014). COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med, 6, 242ra84.
DOI
|
23 |
Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu(R)) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4.
DOI
ScienceOn
|